Macrosphelide A Exhibits a Specific Anti-Cancer Effect by Simultaneously Inactivating ENO1, ALDOA, and FH.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Aerobic glycolysis, or the Warburg effect, is a critical hallmark of cancer, distinguishing cancer cells from normal cells.
• Targeting this metabolic adaptation offers a promising strategy for selective cancer therapy.
• Macrosphelide A (MSPA) is a potential anti-cancer drug candidate, but its mechanism in cancer metabolism is not well understood.

Purpose of the Study:

• To investigate the role of Macrosphelide A (MSPA) in modulating cancer metabolism.
• To identify MSPA target proteins and elucidate its mechanism of action against cancer cells.

Main Methods:

• Proteomics combined with affinity chromatography to screen MSPA target proteins.
• In vitro binding assays, competition assays, and simulation modeling to confirm direct interactions.
• siRNA-based knockdown and cell-based assays (glucose consumption, lactate release) to assess MSPA's effects.
• Enzyme inhibition assays to evaluate MSPA's impact on key glycolytic enzymes.

Main Results:

• MSPA directly interacts with aldolase A (ALDOA), enolase 1 (ENO1), and fumarate hydratase (FH).
• MSPA treatment significantly reduced glucose uptake and lactate production in HepG2 cells.
• MSPA inhibited cancer cell proliferation and induced apoptosis by targeting ENO1, ALDOA, and FH.

Conclusions:

• MSPA exhibits anti-cancer properties by simultaneously inhibiting ENO1, ALDOA, and FH, critical enzymes in the Warburg effect.
• MSPA represents a potential therapeutic agent for cancer by targeting its unique metabolic pathways.